GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Intravenous Infusions Ltd (XGHA:IIL) » Definitions » Short-Term Capital Lease Obligation

Intravenous Infusions (XGHA:IIL) Short-Term Capital Lease Obligation : GHS0.00 Mil (As of . 20)


View and export this data going back to 2015. Start your Free Trial

What is Intravenous Infusions Short-Term Capital Lease Obligation?

Intravenous Infusions's Short-Term Capital Lease Obligation for the quarter that ended in . 20 was GHS0.00 Mil.


Intravenous Infusions Short-Term Capital Lease Obligation Historical Data

The historical data trend for Intravenous Infusions's Short-Term Capital Lease Obligation can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Intravenous Infusions Short-Term Capital Lease Obligation Chart

Intravenous Infusions Annual Data
Trend
Short-Term Capital Lease Obligation

Intravenous Infusions Semi-Annual Data
Short-Term Capital Lease Obligation

Intravenous Infusions Short-Term Capital Lease Obligation Explanation

Short-Term Capital Lease Obligation represents the total amount of Long-Term Capital Lease Obligation that must be paid within the next accounting period. Capital lease obligations are contractual obligations that arise from obtaining the use of property or equipment via a capital lease contract.


Intravenous Infusions Short-Term Capital Lease Obligation Related Terms

Thank you for viewing the detailed overview of Intravenous Infusions's Short-Term Capital Lease Obligation provided by GuruFocus.com. Please click on the following links to see related term pages.


Intravenous Infusions (XGHA:IIL) Business Description

Traded in Other Exchanges
N/A
Address
Plot 4/7 Blk L, P.O Box KF 63, Effiduase-Koforidua, GHA
Intravenous Infusions Ltd engages in the production of intravenous infusion and small-volume injectables for therapeutic purposes. The product categories are IV fluids, giving sets, and small-volume injectables. The company earns a majority of its revenue from IV fluids. Some of the IV fluids are sodium chloride solutions, dextrose solutions, dextrose saline solutions, and dextran solutions. Small-volume injectables include pethidine injection, magnesium sulphate injection, and quinine injection. Giving sets include plain giving sets, and blood giving sets.

Intravenous Infusions (XGHA:IIL) Headlines

From GuruFocus

Q3 2021 Morgan Stanley Earnings Call Transcript

By GuruFocus Research 01-23-2024

Q4 2022 Morgan Stanley Earnings Call Transcript

By GuruFocus Research 01-23-2024

Q3 2023 Morgan Stanley Earnings Call Transcript

By GuruFocus Research 01-23-2024

Q2 2023 Morgan Stanley Earnings Call Transcript

By GuruFocus Research 01-23-2024

Q3 2022 Morgan Stanley Earnings Call Transcript

By GuruFocus Research 01-23-2024

Q1 2022 Morgan Stanley Earnings Call Transcript

By GuruFocus Research 01-23-2024